Lifestance Health Group Inc

Outpatient and specialty care stocks tracked by the publication reported strong second-quarter results, with revenues beating analysts' consensus estimates by 2.6% and next quarter's revenue guidance coming in 3.3% above expectations. U.S. Physical Therapy reported revenues of $214.1 million, up 8.5% year on year, exceeding expectations by 1.9% but missing EPS estimates significantly. LifeStance Health Group delivered the biggest analyst estimate beat, fastest revenue growth, and highest full-year guidance raise in the group, with revenues of $435.4 million, up 26.1% year on year. DaVita reported revenues of $3.55 billion, up 5.2% year on year, but missed full-year EPS guidance estimates and delivered the weakest performance against analyst estimates among its peers. Surgery Partners reported revenues of $848.9 million, up 2.7% year on year, beating expectations by 2.2%, while agilon health reported revenues of $1.49 billion, up 7.2% year on year, surpassing expectations by 2.8% and delivering the highest guidance raise in the group.

The six outpatient and specialty care stocks tracked by this publication reported a strong first quarter, with revenues beating analysts' consensus estimates by 2% and next quarter's revenue guidance coming in 5.9% above expectations. Encompass Health reported revenues of 1.59 billion dollars, up 9% year on year and exceeding estimates by 1.2%, while agilon health posted revenues of 1.42 billion dollars, down 7.3% year on year but beating estimates by 3.2% and delivering the highest guidance raise among its peers. U.S. Physical Therapy, the weakest performer, reported revenues of 198.3 million dollars, up 7.9% year on year and in line with expectations, but significantly missed analysts' EPS estimates. LifeStance Health Group recorded revenues of 403.5 million dollars, up 21.2% year on year and topping estimates by 4.2%, achieving the fastest revenue growth and biggest analyst estimate beat in the group. DaVita reported revenues of 3.42 billion dollars, up 6% year on year and surpassing estimates by 2.1%, with a beat on both EPS and full-year EPS guidance. Since their latest earnings results, share prices of these outpatient and specialty care stocks have risen 62.3% on average.

Seeking Alpha's quantitative framework has identified Centene Corporation as the highest-rated healthcare stock with a Strong Buy rating of 4.97, while Doximity received the lowest rating of 1.21, a Strong Sell, as the second-quarter earnings season begins. The Health Care Select Sector SPDR Fund ETF, which tracks the sector and represents roughly 12.12% of the S&P 500, has risen 4.52% year-to-date, trailing the benchmark index's 10.06% advance. In the second quarter, the broader healthcare sector posted a modest 8.78% return, while the Technology index skyrocketed 43.49%. The top five Strong Buy stocks with market caps above $2 billion also include Liquidia Corporation at 4.95, BrightSpring Health Services at 4.95, LifeStance Health Group at 4.93, and PACS Group at 4.92. The bottom five Strong Sell or Sell stocks include TransMedics Group at 1.26, CSL Limited at 1.30, Zoetis at 1.34, and EssilorLuxottica ADR at 1.39.

William Blair updated its July Analyst Conviction List, adding Oracle, American Express, Ecolab, Comfort Systems USA, Boot Barn, LifeStance Health, Genmab, Silence Therapeutics, Tyra Biosciences, Arxis, Novanta, Dynatrace, Everpure, and ServiceTitan. The firm said Oracle is emerging as a major beneficiary of the AI infrastructure buildout, with hyperscale cloud commitments driving record remaining performance obligations and stronger revenue visibility. Removed stocks included Meta Platforms, Chewy, SharkNinja, Chime, Flywire, LPL Financial, Palomar, Exponent, GFL Environmental, Encompass Health, Waystar, Insmed, LENZ Therapeutics, Ocular Therapeutix, Curtiss-Wright, Mayville Engineering, Standex, Arista Networks, Guidewire, JLL, Procore, and Rubrik, all through automatic six-month removals. Axsome Therapeutics was removed after FDA approval for Auvelity in Alzheimer’s disease agitation and a roughly 48% gain since its April addition, while Rollins was removed as near-term growth and margin trends looked less clear.

LifeStance Health Group has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting a positive shift in its earnings outlook. The upgrade is driven by a 42.3% increase in the Zacks Consensus Estimate for the company over the past three months. For the fiscal year ending December 2026, the outpatient mental health services provider is expected to earn $0.12 per share, unchanged from the prior year. The Zacks Rank system places LifeStance Health in the top 5% of more than 4,000 covered stocks, indicating superior earnings estimate revision activity that could lead to near-term stock price gains.